Anti-atherosclerotic and anti-diabetic properties of probucol and related compounds

被引：43

作者：

Tanous, David ^{[2
]}

Hime, Neil ^{[1
]}

Stocker, Roland ^{[1
]}

机构：

[1] Univ Sydney, Discipline Pathol, Sydney, NSW 2006, Australia

[2] Univ Hlth Network, Toronto Gen Hosp, Toronto Congenital Cardiac Ctr Adults, Toronto, ON M5G 1L7, Canada

来源：

REDOX REPORT | 2008年 / 13卷 / 02期

关键词：

probucol; type; 2; diabetes; atherosclerosis;

D O I：

10.1179/135100008X259196

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Probucol is a diphenolic compound with anti-oxidant and anti-inflammatory properties that reduces atherosclerosis and restenosis. Unfortunately, adverse effects on blood lipoproteins and cardiac electrophysiology have curtailed its use as a drug. Compounds related to probucol that have improved efficacy without the adverse effects offer promise as novel therapies of cardiovascular disease. Recent results suggest that these compounds may be used for the prevention of type 2 diabetes, a disease that is increasing in prevalence and importance world-wide. In this review, the molecular mechanisms underlying the beneficial activities of probucol and related compounds are described.

引用

页码：48 / 59

页数：12

共 110 条

[1] Autoimmunity and β cell regeneration in mouse and human type 1 diabetes -: The peace is not enough [J].

Ablamunits, Vitaly ;

Sherry, Nicole A. ;

Kushner, Jake A. ;

Herold, Kevan C. .

HOW DO WE BEST EMPLOY ANIMAL MODELS FOR TYPE 1 DIABETES AND MULTIPLE SCLEROSIS?, 2007, 1103 :19-32

[2]

Agardh E, 2000, CURR EYE RES, V21, P543, DOI 10.1076/0271-3683(200007)21:1

[3]

1-Z

[4]

FT543

[5] Nrf2, a Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene [J].

Alam, J ;

Stewart, D ;

Touchard, C ;

Boinapally, S ;

Choi, AMK ;

Cook, JL .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (37) :26071-26078

[6] THE EFFECT OF CHOLESTEROL-LOWERING AND ANTIOXIDANT THERAPY ON ENDOTHELIUM-DEPENDENT CORONARY VASOMOTION [J].

ANDERSON, TJ ;

MEREDITH, IT ;

YEUNG, AC ;

FREI, B ;

SELWYN, AP ;

GANZ, P .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (08) :488-493

[7] INCREASED OXIDIZABILITY OF PLASMA-LIPOPROTEINS IN DIABETIC-PATIENTS CAN BE DECREASED BY PROBUCOL THERAPY AND IS NOT DUE TO GLYCATION [J].

BABIY, AV ;

GEBICKI, JM ;

SULLIVAN, DR ;

WILLEY, K .

BIOCHEMICAL PHARMACOLOGY, 1992, 43 (05) :995-1000

[8]

Barnhart J. W., 1991, ANTILIPIDEMIC DRUGS, P277

[9] Effects of torcetrapib in patients at high risk for coronary events [J].

Barter, Philip J. ;

Caulfield, Mark ;

Eriksson, Mats ;

Grundy, Scott M. ;

Kastelein, John J. P. ;

Komajda, Michel ;

Lopez-Sendon, Jose ;

Mosca, Lori ;

Tardif, Jean-Claude ;

Waters, David D. ;

Shear, Charles L. ;

Revkin, James H. ;

Buhr, Kevin A. ;

Fisher, Marian R. ;

Tall, Alan R. ;

Brewer, Bryan .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) :2109-2122

[10] ROLE OF OXIDATIVE STRESS IN DEVELOPMENT OF COMPLICATIONS IN DIABETES [J].

BAYNES, JW .

DIABETES, 1991, 40 (04) :405-412

← 1 2 3 4 5 6 7 8 9 10 →